Tech Company Financing Transactions
Ataxion Funding Round
Ataxion, based in Cambridge, received $17 million in investment from Atlas Venture and Biogen Idec.
Transaction Overview
Company Name
Announced On
3/19/2014
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Atlas Venture (Joshua Resnick)
Biogen Idec (Steven Holtzman)
Proceeds Purpose
In addition to participating in the Series A investment, Biogen Idec is providing non-dilutive R&D and other funding to Ataxion. Biogen Idec will have the option to acquire Ataxion to continue development of the program upon completion of the Phase 1 multiple ascending dose (MAD) study at pre-negotiated terms, including upfront and milestone payments.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
25 1st St. 303
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Resnick
Browse more venture capital transactions:
Prev: 3/19/2014: Cloud4Wi venture capital transaction
Next: 3/19/2014: Spritz Technology venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs